Isomorphic Labs

Isomorphic Labs is a UK-based drug discovery company and spinout of DeepMind, a division of Google AI. Isomorphic launched in 2021 under the DeepMind parent company Alphabet with CEO Demis Hassabis. DeepMind’s AlphaFold 2 AI technology is able to predict the structure of proteins from amino acid sequences. In addition to protein folding structure, AlphaFold can predict structures of other biological molecules including protein-ligand structures, proteins bound to nucleic acids and post-translational modifications. In 2024, company entered into partnerships with Eli Lilly and Novartis to apply AI to discovery of new medications. Isomorphic plans to use AlphaFold and other AI technology to better understand biological mechanisms of drug target and rationally design novel therapeutics. The collaboration between Isomorphic and Novartis was reported to involve the development of small molecule therapeutics against three undiscosed targets.

Isomorphic Labs is a UK-based drug discovery company and spinout of DeepMind, a division of Google AI. Isomorphic launched in 2021 under the DeepMind parent company Alphabet with CEO Demis Hassabis. DeepMind’s AlphaFold 2 AI technology is able to predict the structure of proteins from amino acid sequences. In 2024, company entered into partnerships with Eli Lilly and Novartis to apply AI to discovery of new medications. Isomorphic plans to use AlphaFold and other AI technology to better understand biological mechanisms of drug target and rationally design novel therapeutics.